Explore

Trendline Trendline
Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter
Trendline Trendline
Longeveron Outlines Strategic Focus and Key Milestones for 2026

Longeveron Outlines Strategic Focus and Key Milestones for 2026

Longeveron Outlines Strategic Focus and Key Milestones for 2026
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth
Trendline Trendline
Halia Therapeutics Expands Leadership with New Executive Chairman and Directors

Halia Therapeutics Expands Leadership with New Executive Chairman and Directors

Halia Therapeutics Expands Leadership with New Executive Chairman and Directors
Trendline Trendline
Halia Therapeutics Expands Leadership as It Advances Inflammation Therapies

Halia Therapeutics Expands Leadership as It Advances Inflammation Therapies

Halia Therapeutics Expands Leadership as It Advances Inflammation Therapies
Trendline Trendline
Vistagen Appoints Angel S. Angelov as Chief Medical Officer to Enhance Neurocircuitry Product Development

Vistagen Appoints Angel S. Angelov as Chief Medical Officer to Enhance Neurocircuitry Product Development

Vistagen Appoints Angel S. Angelov as Chief Medical Officer to Enhance Neurocircuitry Product Development
Trendline Trendline
BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results
Trendline Trendline
Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate

Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate

Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate